Portland, Oregon , Oct. 20, 2016 -- Signal Bay, Inc. (OTC PINK: SGBY) the market leader in cannabis testing and laboratory services announced today the completion of the purchase of GreenHaus Analytical Labs. The Portland based lab brings the total number of laboratories now operating as part of the EVIO Labs division to four.
CEO William Waldrop stated, "Portland is by far the largest market in Oregon for analytical cannabis testing services and this latest acquisition completes our previously stated goal of building out a "spoke & hub" business model that ensures EVIO Labs can provide a full suite of testing services across the state."
Mr. Waldrop also stated, "The recent changes in Oregon’s cannabis testing requirements in the midst of the fall cannabis harvest has created an extraordinary demand for accurate and timely testing services which we can now provide with full confidence statewide. As of this acquisition, we now have 23 total employees working to meet demand."
Mr. Waldrop continued, “GreenHaus Analytical Labs is an ORELAP accredited lab licensed by the OLCC. Henry Grimmett, the founder of GreenHaus Analytical will join Signal Bay as the newly appointed President of the EVIO Labs division. Mr. Grimmett brings a wealth of experience to Signal Bay including years of outdoor cultivation experience in Humboldt County, California and extensive study and research of plant physiology and plant bio-chemistry at San Diego State University.”
Mr. Waldrop also stated, "The GreenHaus team is a welcome addition to Signal Bay. Henry’s appointment brings proven leadership, expertise, and a wealth of contacts to our EVIO Labs division that will guarantee operational success as we expand our lab division from Oregon into California and across the country. We will have more information on our recently announced California acquisition soon.”
About Signal Bay, Inc.: Signal Bay, Inc. is the Oregon-based Life Sciences company. Through its three subsidiaries: Signal Bay Research, Signal Bay Services and EVIO Labs; the Company provides research, consulting services, and analytical testing services to the legal cannabis industry. The Company's EVIO Labs division operates state-of-the-art testing facilities and offers accredited testing methodologies performed by a qualified team of scientists to ensure the safety and quality of the nation's cannabis supply. Learn more at http://SignalBay.com or the company can be reached directly @ 1-888-544-EVIO.
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at www.sec.gov or https://signalbay.com/investors.
Investor Contact: William Waldrop, CEO [email protected] (541) 633-4568


FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 



